REVA Medical's MOTIV Sirolimus-Eluting Scaffold Shows Superior Results in Critical Limb Ischemia Trial

Key Takeaways

• MOTIV BTK randomized pivotal trial met its primary efficacy endpoint for critical limb-threatening ischemia treatment
• MOTIV sirolimus-eluting bioresorbable vascular scaffold demonstrated early and sustained clinical benefits in complex patient population
• Results presented at Charing Cross International Symposium could advance regulatory approval pathway for CLTI treatment

---

SAN DIEGO - REVA Medical, LLC announced that its MOTIV BTK randomized pivotal clinical trial successfully met the primary efficacy endpoint, demonstrating superiority of the MOTIV® sirolimus-eluting bioresorbable vascular scaffold in treating patients with critical limb-threatening ischemia (CLTI).

The company presented the positive results at the Charing Cross International Symposium, marking a significant milestone for patients facing this severe cardiovascular condition that threatens limb viability.

Trial Demonstrates Clinical Superiority

The MOTIV BTK trial evaluated the bioresorbable scaffold’s performance in a complex patient population suffering from CLTI, a condition characterized by severely reduced blood flow to the extremities. The trial’s success in meeting its primary endpoint suggests the device provides meaningful clinical benefits over existing treatment options.

Critical limb-threatening ischemia represents one of the most challenging conditions in vascular medicine, often leading to amputation when conventional treatments fail. The positive trial results indicate that REVA Medical’s sirolimus-eluting scaffold technology may offer a new therapeutic approach for these high-risk patients.

Market Impact and Clinical Significance

The successful trial outcome positions REVA Medical to advance its regulatory strategy for the MOTIV scaffold. Bioresorbable vascular scaffolds represent an evolving technology in interventional cardiology and vascular medicine, designed to provide temporary structural support while gradually dissolving in the body.

The sirolimus drug coating on the MOTIV scaffold is intended to prevent restenosis, a common complication where treated blood vessels narrow again over time. The combination of bioresorbable technology with proven anti-proliferative medication addresses key limitations of traditional permanent metal stents.

For the broader cardiovascular device market, these results validate the potential of next-generation bioresorbable technologies in treating complex vascular conditions. The positive outcome may accelerate adoption of similar technologies across the industry.

Regulatory and Commercial Pathway

With primary endpoint achievement, REVA Medical can now advance toward regulatory submissions for market approval. The company’s focus on CLTI addresses a significant unmet medical need, potentially supporting expedited regulatory review pathways.

The presentation at the prestigious Charing Cross International Symposium provides important clinical validation and visibility within the global vascular medicine community, supporting future commercial adoption.

---

Frequently Asked Questions

What does this mean for patients with critical limb-threatening ischemia?

The positive trial results suggest patients may have access to a new treatment option that provides superior clinical benefits compared to existing therapies, potentially reducing amputation risk and improving limb salvage outcomes.

When will the MOTIV scaffold be available to patients?

REVA Medical must complete regulatory submissions and receive approval from health authorities before commercial availability. Timeline depends on regulatory review processes, which typically take 6-18 months for medical devices.

How does the MOTIV scaffold differ from traditional stents?

Unlike permanent metal stents, the MOTIV scaffold is bioresorbable, meaning it gradually dissolves in the body while providing temporary support. It’s also coated with sirolimus to prevent vessel re-narrowing.